Streamlined.financeStreamlined.finance
MarketsFind Stocks

Organon & Co.

NYSE

Market Cap.

4.6B

Avg. Volume

1.93M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Organon & Co.

Organon & Co. News

Organon & Co. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareDrug Manufacturers - General
organon.com

About Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Organon & Co. Earnings & Revenue

Organon & Co. Financials

Table Compare

Compare OGN metrics with:

   

Earnings & Growth

OGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Organon & Co. Income

Organon & Co. Balance Sheet

Organon & Co. Cash Flow

Organon & Co. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsBuy
Debt/Equity RatioStrong Sell
Price/Earnings RatioNeutral
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Organon & Co. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

1.1200

Payment DateDividendFrequency
2024-09-120.28Quarterly
2024-06-130.28Quarterly
2024-03-140.28Quarterly
2023-12-140.28Quarterly
2023-09-140.28Quarterly

Organon & Co. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Organon & Co. Executives

NameRole
Mr. Kevin AliChief Executive Officer & Director
Mr. Matthew M. WalshExecutive Vice President & Chief Financial Officer
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & Supply
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate Secretary
Ms. Susanne Gabriele FiedlerExecutive Vice President & Chief Commercial Officer
NameRoleGenderDate of BirthPay
Mr. Kevin AliChief Executive Officer & DirectorMale19603.82M
Mr. Matthew M. WalshExecutive Vice President & Chief Financial OfficerMale19671.81M
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & SupplyMale19651.54M
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate SecretaryMale19741.44M
Ms. Susanne Gabriele FiedlerExecutive Vice President & Chief Commercial OfficerFemale19681.38M

Organon & Co. Insider Trades

Date9 Sep
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares0
Date29 Mar
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares42553
Date9 Sep
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares28996
Date3 Sep
NameAli Kevin
RoleChief Executive Officer
TransactionAcquired
TypeA-Award
Shares21567
Date3 Sep
NameAli Kevin
RoleChief Executive Officer
TransactionDisposed
TypeF-InKind
Shares11927
DateNameRoleTransactionTypeShares
9 SepKarp DanielExecutive VP, Corp. Dev.Disposed0
29 MarKarp DanielExecutive VP, Corp. Dev.Disposed42553
9 SepKarp DanielExecutive VP, Corp. Dev.Disposed28996
3 SepAli KevinChief Executive OfficerAcquiredA-Award21567
3 SepAli KevinChief Executive OfficerDisposedF-InKind11927

Discover More

Streamlined Academy

Organon & Co.

NYSE

Market Cap.

4.6B

Avg. Volume

1.93M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Organon & Co. News

Organon & Co. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Organon & Co. Earnings & Revenue

Organon & Co. Income

Organon & Co. Balance Sheet

Organon & Co. Cash Flow

Organon & Co. Financials Over Time

Organon & Co. Executives

NameRole
Mr. Kevin AliChief Executive Officer & Director
Mr. Matthew M. WalshExecutive Vice President & Chief Financial Officer
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & Supply
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate Secretary
Ms. Susanne Gabriele FiedlerExecutive Vice President & Chief Commercial Officer
NameRoleGenderDate of BirthPay
Mr. Kevin AliChief Executive Officer & DirectorMale19603.82M
Mr. Matthew M. WalshExecutive Vice President & Chief Financial OfficerMale19671.81M
Mr. Joseph T. Morrissey Jr.Executive Vice President and Head of Manufacturing & SupplyMale19651.54M
Mr. Kirke WeaverExecutive Vice President, General Counsel & Corporate SecretaryMale19741.44M
Ms. Susanne Gabriele FiedlerExecutive Vice President & Chief Commercial OfficerFemale19681.38M

Organon & Co. Insider Trades

Date9 Sep
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares0
Date29 Mar
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares42553
Date9 Sep
NameKarp Daniel
RoleExecutive VP, Corp. Dev.
TransactionDisposed
Type
Shares28996
Date3 Sep
NameAli Kevin
RoleChief Executive Officer
TransactionAcquired
TypeA-Award
Shares21567
Date3 Sep
NameAli Kevin
RoleChief Executive Officer
TransactionDisposed
TypeF-InKind
Shares11927
DateNameRoleTransactionTypeShares
9 SepKarp DanielExecutive VP, Corp. Dev.Disposed0
29 MarKarp DanielExecutive VP, Corp. Dev.Disposed42553
9 SepKarp DanielExecutive VP, Corp. Dev.Disposed28996
3 SepAli KevinChief Executive OfficerAcquiredA-Award21567
3 SepAli KevinChief Executive OfficerDisposedF-InKind11927

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
organon.com

About Organon & Co.

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Organon & Co.

Organon & Co. Financials

Table Compare

Compare OGN metrics with:

   

Earnings & Growth

OGN

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

OGN

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

OGN

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

OGN

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Organon & Co. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

1.1200

Payment DateDividendFrequency
2024-09-120.28Quarterly
2024-06-130.28Quarterly
2024-03-140.28Quarterly
2023-12-140.28Quarterly
2023-09-140.28Quarterly

Organon & Co. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Buy
Return on AssetsBuy
Debt/Equity RatioStrong Sell
Price/Earnings RatioNeutral
Price/Book RatioStrong Sell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)